AFP is used as a tumor marker to help detect and diagnose cancers of the liver, testes, and ovaries. Though the test is often ordered to monitor people with chronicliver diseases such as cirrhosis, chronic hepatitis B or hepatitis C because they have an increased lifetime risk of developing liver cancer, most current guidelines do not recommend this use. A doctor may order an AFP test, along with imaging studies, to try to detect liver cancer when it is in its earliest and most treatable stages.
If a person has been diagnosed with hepatocellular carcinoma or another form of AFP-producing cancer, an AFP test may be ordered periodically to help monitor the person's response to therapy and to monitor for cancer recurrence.
An AFP-L3% is sometimes also ordered to compare the amount of the AFP variant called AFP-L3 to the total amount of AFP. The AFP-L3% test is not yet widely used in the U.S. but has gained wider acceptance in other countries such as Japan. The test is used to help evaluate the risk of developing hepatocellular carcinoma, especially in those with chronic liver disease, and also to evaluate response of hepatocellular carcinoma to treatment.
It is suspected that someone has liver cancer or certain cancers of the testes or ovaries; cancer may be suspected when, for example, lumps are felt in the abdominal area during a physical exam or when imaging tests detect possible tumors.
Someone who has been diagnosed with and treated for a cancer of the liver, testes, or ovaries is being monitored for the effectiveness of treatment
Someone is being monitored for cancer recurrence
An AFP-L3% is sometimes ordered to help evaluate the risk of hepatocellular carcinoma when a person has chronicliver disease or to test the effectiveness of treatment of of hepatocellular carcinoma or monitor for its recurrence.
Increased AFP levels may indicate the presence of cancer, most commonly liver cancer, cancer of the ovary, or germ cell tumor of the testes. However, not every liver, ovarian, or testicular cancer will produce significant quantities of AFP. Elevated levels may sometimes be seen with other cancers such as stomach, colon, lung, breast, and lymphoma, although it is rarely ordered to evaluate these conditions. Other diseases such as cirrhosis and hepatitis can also cause increased levels.
When AFP is used as a monitoring tool, decreasing levels indicate a response to treatment. If concentrations after cancer treatment do not significantly decrease, usually to normal or near normal levels, then some of the tumor tissue may still be present. If concentrations begin to increase, then it is likely that the cancer is recurring. However, since AFP can be increased in hepatitis or cirrhosis, AFP levels can sometimes be misleading. If AFP levels are not elevated prior to treatment, then the test will not generally be useful to monitor the effectiveness of treatment or to monitor for recurrence.
When the AFP concentrations of people with chronic liver disease go from moderately elevated to greatly elevated, their risk of developing liver cancer increases. When total AFP and AFP-L3% are significantly elevated, then the affected person has an increased risk of having or developing hepatocellular carcinoma in the next year or two. However, both AFP and AFP-L3% concentrations can be elevated, and fluctuate, in people with chronic hepatitis and cirrhosis. In these cases, a sharp increase in AFP is more important than the actual numerical value of the test result.
Not every person with increased AFP and AFP-L3% test results has cancer or will develop liver cancer. The AFP and AFP-L3% tests are not diagnostic; they are indicators. They must be used in conjunction with information from a history and physical examination as well as imaging studies to look for the development of tumors. Although these tests can provide useful information, they are not as specific or sensitive as doctors would wish. AFP can temporarily increase whenever the liver is injured and regenerating, and moderate elevations can be seen with a variety of conditions. Because of this, AFP testing can give some false positives. In addition, not every cancer will produce AFP, so a person could still have cancer even when the AFP is normal. For these reasons, the AFP test should not be used to screen the general population for cancer.
AFP is not only a tumor marker. Because AFP is produced by the fetus, levels are normally higher in pregnant women and in their newborns. For more information on AFP testing during pregnancy, see Triple or Quad Screen.
This article was last reviewed on December 3, 2012. | This article was last modified on October 1, 2015.
The review date indicates when the article was last reviewed from beginning to end to ensure that it reflects the most current science. A review may not require any modifications to the article, so the two dates may not always agree.
The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.